



Handle with care: A systematic review on frailty in cardiac care and its usefulness in heart transplantation



Oliver Mauthner ^{a,*}, Veerle Claes ^{a,b}, Mieke Deschodt ^{a,b}, Sunita R. Jha ^{c,d}, Sandra Engberg ^e, Peter S. Macdonald ^{c,f}, Phillip J. Newton ^d, Sabina De Geest ^{a,b}

^a Institute of Nursing Science, Faculty of Medicine, University of Basel, Switzerland

^b Academic Centre for Nursing and Midwifery, Department of Public Health and Primary Care, KU Leuven, Belgium

^c Heart Transplant Program, St Vincent's Hospital, Sydney, Australia

^d Centre for Cardiovascular and Chronic Care, Faculty Health, University of Technology Sydney

^e School of Nursing, University of Pittsburgh, USA

^f Victor Chang Cardiac Research Institute, Sydney, NSW

ABSTRACT

Background: There is growing consensus that frailty, a state of vulnerability and a decline in functioning across multiple physiological body systems, is a valuable criterion to guide clinicians' risk prediction for poor outcomes in adult transplant candidates. In its 2016 listing criteria for heart transplantation the International Society for Heart Lung Transplantation recommends frailty assessment. We aimed to summarize the usefulness of frailty assessment in heart transplant candidates or recipients reported throughout the literature.

Methods: We performed a systematic literature search in PubMed to identify papers reporting on frailty in transplantation, chronic heart failure, and ventricular assist device implantation published over the last 10 years in English. Additionally, a hand search was conducted, including manually searching the reference lists and a citation search of relevant papers.

Results: Eleven primary research articles were included in this systematic review. Frailty is a risk factor for morbidity, hospitalization, and mortality in patients with advanced heart failure and individuals being considered for ventricular assist device implantation. Of the patients being considered for transplantation, 33% are frail. The Frailty Phenotype by Fried is a particularly useful tool to quickly identify higher risk patients for adverse outcomes.

Conclusion: A lack of standardization and limited evidence on frailty in transplantation limit its use as a definitive listing criterion. Future research efforts should focus on systematic integration of frailty measures in transplant practice.

© 2017 Elsevier Inc. All rights reserved.

1. Introduction

Frailty is one of the most critical issues for healthcare due to its inherent relationship with poor clinical outcomes [1–3]. It has been defined as a cumulative decline across physiological body systems, depleting a person's ability to maintain homeostasis when faced with stressors [4–6]. Individuals undergoing organ transplantation face several major stressors, and frail transplant patients are more likely to experience sudden disproportionate deteriorations in health status compared with non-frail patients [4–6]. Following these recent insights, in their 10-year update of assessment criteria for heart transplantation the International Society for Heart Lung Transplantation (ISHLT) has recommended that patients being evaluated for heart transplantation be assessed for frailty [7]. Frailty assessment is deemed particularly relevant since respectively 20% and 17% of heart transplant candidates and recipients in the United States of America (US) are ≥65 years of age, with

similar figures reported in Europe [8–10]. It is postulated that frailty can provide an important contribution to the limited evidence base to guide clinical decision-making for transplant candidacy and optimal clinical management for this older cohort [11,12]. Since frailty assessment is endorsed by ISHLT, it is timely that transplant clinicians understand the concept of frailty, its measurement in clinical practice, and outcomes. Therefore, we aimed to summarize the usefulness of frailty assessment in heart transplant candidates, recipients, and individuals being considered for destination therapy. This systematic review is expanding on a previous work on frailty in heart failure patients [13] to include specific new subgroups of populations, and to identify new evidence up to the present time.

1.1. Frailty: two distinct conceptual models that serve different purposes

Two main conceptual approaches to measuring frailty have been developed over the past 15 years. Even though there is now broad agreement on the definitions and conceptualization of the syndrome, there is no consensus on which instrument is best suited to measure frailty. [14–16] The Frailty Phenotype (FP) focuses on physical aspects of frailty

* Corresponding author at: Institute of Nursing Science, Faculty of Medicine, University of Basel, Bernoullistrasse 28, CH-4056, Basel, Switzerland. Tel.: +41 61 267 09 54 (Business), +41 76 419 33 60 (Home); fax: +41 61 267 09 55.

E-mail address: oliver.mauthner@unibas.ch (O. Mauthner).

comorbidities, which provides a major advantage for using this conceptual model.

2. Methods

2.1. Identification of relevant papers

We performed a systematic review of articles published in English over the last ten years in PubMed, followed by a citation search. A search string was built combining MeSH terms and free text words related to 'frailty' and 'transplantation' (Fig. 1). Additionally, the reference lists of studies meeting eligibility criteria were screened for relevant papers that might have been missed through the electronic search.

2.2. Selection of relevant papers

We included papers reporting on frailty in heart transplantation, chronic heart failure and ventricular assist device (VAD) implantation. Heart failure patients requiring either bridge-to-transplant or destination VAD therapy are included in this review due to the very limited evidence pertaining to cardiac transplantation alone. Quantitative studies were included if a defined measure of frailty was assessed in a cohort of heart transplant candidates or recipients, heart failure patients, or VAD recipients. Qualitative studies, doctoral theses, books and book chapters, and case studies were excluded.

The titles and abstracts of potentially relevant papers were screened using the predefined inclusion and exclusion criteria. Then the full text articles were obtained from all abstracts meeting inclusion criteria and were further screened for eligibility. Two researchers (OM, VC) independently performed the selection and inclusion of articles,

with differences being resolved through discussion with a third member (SRJ).

2.3. Data extraction and summarizing

An initial data-charting format was developed by two researchers (OM, VC). Iterative discussions within the research team guided small adjustments during the data charting process. The final version entailed information concerning prevalence, morbidity, and mortality about frailty in transplantation, chronic heart failure, and VAD implantation. Data from the included studies were extracted by one researcher (OM) and double-checked by a second reviewer (VC). The methodological quality of the studies was checked using The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) instrument of the Equator Network. The review process was reported based on the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA).

3. Results

The database search produced 1713 articles for screening (Fig. 1). After screening of titles, abstracts and full texts, 11 studies [30–40] were included and summarized in this paper (Table 3). Although over the past 10 years a rapid growing body of evidence has highlighted frailty as a highly prevalent and novel predictor for clinically relevant adverse outcomes in general [20], only one study assessing frailty in patients referred for heart transplantation could be identified [30]. Nevertheless, frailty has been examined more intensively in the related field of chronic heart failure, as well as mechanical circulatory support implant and is thus included in this review [31–40].




Fig. 1. Search retrieval process.

Table 3

Summary of included articles on frailty in cardiac transplantation, including frailty in heart failure, and LVAD therapy and their impact on outcomes.

References, Country	Design	Setting/Sample	n	Patients	Frailty Measure	Prevalence of frailty	Clinical Outcomes
Jha et al. [30] Australia	Prospective cohort	Outpatients referred for transplant assessment	120	53 ± 12 years; 83% males	Modified FP	33%	Mortality HR 2.07 (95% CI; 1.01–4.26)
Madan et al. [31] USA	Single-center pilot study	Outpatients with CHF	40	74.9 ± 6.5 years; 42% males	FP	65%	All-cause hospitalization HR 1.92 (CI 95% 1.12–3.27; <i>P</i> = 0.017) Non-HF hospitalizations HR 3.31 (95% CI 1.14–9.6; <i>P</i> = 0.380) Mortality HR 1.93 (95% CI; 1.15–3.25, <i>P</i> = 0.013)
Reeves et al. [32]	Prospective 3 age-matched cohort	Patients hospitalized with acute decompensated heart failure (HF) matched with a) stable HF with preserved EF, b) stable HF with reduced EF, c) healthy older adults	27	72.9 ± 10 years; 41% males	FP	56%	Severe reduction in all domains of physical function, with ≈50% lower in acute decompensated heart failure patients than in stable heart failure or healthy older adults.
Vidan et al. [33]	Prospective cohort	Patients hospitalized for heart failure	450	80 ± 6 years; 50.5% males	FP	76%	Higher risk for functional decline [OR 2.20, 95% CI 1.19–4.08], 1-year all-cause mortality [HR 2.13, 95% CI 1.07–4.23] and 1-year hospital readmission [OR 1.96, 95% CI 1.14–3.34]. HR 2.09 (95% CI 1.11–3.92) q = 0.022 for 1-year mortality
Lupon et al. [34]	Observational Study	Outpatients with CHF	622	68 (29–93) years; 72.5% males	Comprehensive geriatric assessment	40%	Moderate (HR 1.36 95% CI 1.08–1.710) and severe (HR 1.88, 95% CI 1.02–3.47) frailty increased the risk of HF
Khan et al. [35] USA	Secondary analysis	Community dwelling elders	2825	74 ± 3 years; 48% males	Healthy aging and body composition & Gill index	18%	
McNallan et al. [36] USA	Observational study	Community dwelling CHF patients	223	71 ± 14 years; 61% males	FP and deficit index	FP: 21% DI: 0.02–0.075 (± 0.25)	Mortality; FP: HR 2.04 (95% CI 0.99–4.16, q = 0) DI: HR 1.44 (95% CI 1.18–1.76; q = 0) Highly co-morbid: >60% patients had a CCI C3 HR 1.64 (95% CI 1.19–2.26; q = 0.005)
Boxer et al. [37]	Prospective cohort	Outpatients with CHF	60	78 ± 12 years; 72% males	FP	27%	
Pulignano et al. [38] Italy	RCT	Outpatients with CHF	173	UC: n = 87; 78 ± 6 years; 53% males DMP: n = 86 77 ± 6 years; 51% males	Modified frailty score		Higher 1-year mortality (16.9 vs. 4.8%; <i>P</i> < 0.001) Higher rate of hospitalization (20.5 vs. 13.3%; <i>P</i> = 0.01)
Dunlay et al. [39]	Prospective cohort study	Patients undergoing LVAD implant	99	65.1 ± 9.4 years; 72% males	Frailty deficit index	29%	Rehospitalization intermediate frail HR 1.70 (95% CI 1.23–2.34) and 1.42 (95% CI 0.98–2.06) for frail. Intermediate frail (HR 1.70 95% CI 0.71–4.31) and frail (HR 3.08, 95% CI 1.40–7.48) were at risk for death
Chung et al. [40]	Observational cohort study	Patients with advanced HF undergoing VAD implantation	72	59 ± 2 years; 64% males	Hand grip strength a component of FP		Handgrip strength of <25% of body weight showed increased postoperative complications and mortality (bleeding 54 vs 17%; and infections 85 vs 54%), and a lower 6 months survival after the device implant (75.0 vs 92.9%) that persisted up to 3 years following LVAD implant

3.1. Frailty: Its usefulness in clinical transplant practice

3.1.1. Prevalence

Jha et al. [30] assessed frailty in 120 patients (69% men; mean age 53 ± 12 years, mean left ventricular ejection fraction $27 \pm 14\%$), with advanced heart failure referred for cardiac transplantation, using a modified version of the Fried's phenotype, and found that 33% of the patients were frail. Prevalence of frailty was independent of age, gender, heart failure duration, left ventricular ejection fraction, or renal function [30]. In the study by Madan et al. [31] 65% of patients in a heart failure clinic were found to be frail based on the Fried Frailty Phenotype. Reeves and colleagues [32] prospectively conducted a multidimensional assessment (including frailty based on Fried's phenotype) of 27 patients ≥ 60 years of age that had been admitted with acute decompensated heart failure. The team compared study participants' functional performance to 3 age matched cohorts: 1) stable heart failure with preserved ejection fraction, 2) stable heart failure with reduced ejection fraction, and 3) healthy older adults previously enrolled as outpatients. Frailty was common, present in $>50\%$ of participants with acute decompensated heart failure, but was rare or absent in the other cohorts (0% to 14% depending on the cohort) [32]. Vidán and colleagues [33] reported that 75% of non-dependent patients ≥ 70 years of age that were hospitalized for heart failure fulfilled frailty criteria. A study by Lupon et al. [38] emphasized that frailty is more prevalent in older heart failure patients, but could also be observed in younger individuals (<70 years old) with chronic heart failure.

3.1.2. Morbidity and mortality

Khan et al. [35], demonstrate that moderate and severe frailty increased the risk for heart failure incidence (HR 1.36; 95% CI 1.08–1.71 and HR 1.88; 95% CI 1.02–3.47, respectively). Another study conducted by McNallen et al. [36] included community-dwelling individuals with chronic heart failure, of which over 60% had multiple co-morbidities in the presence of frailty, which increased the disease burden. Similarly, in the study by Reeves et al. [32] patients admitted to hospital with heart failure had a severe reduction in all domains of physical function, with scores on the 3 measures of physical functioning (6-min walk distance, Short Physical Performance Battery and gait speed) being approximately 50% lower in the patients with acute decompensated heart failure than in the three age-matched outpatient cohorts (two with stable heart failures and one with health older adults).

There have been few studies investigating the impact of frailty on mortality in chronic heart failure patients, and only one within cardiac transplantation [13]. Specifically, a study by Jha et al. [30] included 120 heart failure patients on the waiting list for transplantation, and reported that frailty was an independent predictor of all-cause mortality, with a mean one year survival of $79\% \pm 5\%$ in the non-frail group compared with $54\% \pm 9\%$ in the frail group ($P < 0.005$). Madan et al. [31] demonstrated that the frailty status of heart failure patients was associated with mortality and all-cause hospitalization (HR 1.93; 95% CI 1.15–3.25, $P = .031$) [31]. Boxer and colleagues [37] followed sixty community dwelling patients with heart failure ($EF \leq 40\%$) in a heart failure center, demonstrating that frailty scores were independently predictive of mortality [HR 1.64, 95% CI 1.19–2.26]. Vidán et al. [33] reported that frail individuals ≥ 70 years of age who were hospitalized for heart failure showed a higher risk for functional decline [OR 2.20, 95% CI 1.19–4.08], 1-year all-cause mortality [HR 2.13, 95% CI 1.07–4.23] and 1-year hospital readmission [OR 1.96, 95% CI 1.14–3.34] than the nonfrail/normal endurance group. Similarly, a study by Pulignano et al. [38] showed a significantly higher rate of hospitalization of frail individuals than in less frail patients (frailty score < 2) (21 versus 13%; $P = 0.01$). Studies in our review highlight that frailty assessment provides valuable prognostic insights in addition to existing risk prediction models.

Concomitantly, many patients with severe heart failure have non-cardiac related comorbidities that render them ineligible for cardiac transplantation and are therefore considered for destination therapy.

Dunlay et al. [39] reported that pre-operative frailty assessment, using the Frailty Index, is associated with worse outcomes following LVAD implant as destination therapy. Patients who were frail at the time of an LVAD implant had an increased risk for mortality (HR 3.08; 95% CI 1.40–7.48). Hazard ratio for re-hospitalization was 1.70 (95% CI 1.23–2.34) for intermediate frail patients, and 1.42 (95% CI 0.98–2.06) in those who were frail (based on tertiles of the deficit index $>0.32 =$ frail, 0.23 to $0.32 =$ intermediate frailty, $<0.23 =$ not frail) [39]. Findings indicate that the risk to be re-hospitalized following device implant is higher in individuals with intermediate frailty. Chung et al. [40] measured handgrip strength, a marker of frailty that is often part of the frailty scoring system, in 72 heart failure patients undergoing VAD implant. Study participants with a handgrip strength of $<25\%$ of body weight showed increased postoperative complications and mortality (bleeding 54% vs 17%; and infections 85% vs 54%), and a lower 6 months survival after the device implant (75.0% vs 92.9%) that persisted up to 3 years following VAD implant.

4. Discussion

The important clinical aspect for transplant professionals is that older individuals with multiple comorbidities require a better risk assessment when evaluating transplant candidacy. Frailty enables clinicians to focus on patients' biological age and has important implications for adverse health outcomes and is being endorsed by various organizations to improve quality of care [16,21]. Of importance, the magnitude of risks associated with frailty, increased comorbidities, and mortality is greater than from current risk predictions. Screening patients using an assessment tool based on the FP is endorsed by the ISHLT and can classify transplant candidates into new and clinically meaningful risk categories. In the management of patients with chronic conditions, disentangling frailty from comorbidities through the FP might be important when assessing chronically ill individuals for transplantation. FP as a screening tool to enhance risk stratification for adverse outcomes in clinical practice is feasible, since no prior clinical information is needed and it takes 10 to 15 min to complete [18,20]. At the same time, assessments based on the FP do not provide insights into underlying factors contributing to a patient's frailty, and thus provide limited guidance towards preventive or therapeutic interventions when frailty is identified. This is a drawback that is addressed by the FI, given its assessment of specific deficits across various domains, enabling clinicians to modify certain aspects of a patient's care to potentially improve frailty. The major disadvantage of the FI is however that it requires a comprehensive geriatric assessment for its scoring, which renders its evaluation time-consuming [41]. It is of key importance for clinicians to understand that the FP and FI cannot be considered equivalent. The optimal choice of approach depends on the purpose, e.g. whether a frailty screening for risk stratification (FP), or a more thorough frailty assessment to tailor patient care is intended (FI).

Risk stratification for frail transplant candidates and recipients, also requires evidence for feasible, effective and scalable interventions to prevent frailty, or to slow its progress. A hallmark of frailty is that the condition can deteriorate or improve over time [5,42–44]. At this point the optimal time to start an intervention to improve frailty is still not clear, especially for individuals being listed for transplantation. Given the fact that it is easier to improve small deficits, rather than larger ones it is recommended to focus on improving patient's functional status when they are pre-frail, rather than frail. Incorporating frailty screening would allow healthcare professionals to systematically identify pre-frail individuals when listing them for cardiac transplantation and initiate pre-rehabilitation. Pre-rehabilitation has shown to result in fewer complications following surgical procedures, as well as decreased hospital stay in non-transplant populations [45]. Also without intervention worsening frailty in older non-transplant populations is common. Since cardiac rehabilitation has been shown to decrease mortality and morbidity in patients with heart failure in both hospital and

community based settings, it thus might also be ideally suited to improve an individual's frailty status prior to transplantation. When patients have been enrolled in pre-rehabilitation further frailty assessments could be conducted to capture when a patient has achieved optimal benefit from the program. Although behavioral interventions focusing on physical activity and/or exercise show potential to improve clinical outcomes [5,6,18,46–50], no interventions have focused specifically on individuals with end stage organ failure and transplant recipients to mitigate effects of frailty.

In addition to building on behavior change science, such work needs to include a better understanding of underlying pathophysiological processes that impact frailty and its interrelationship with cognitive function. Current biological frameworks of frailty etiology point to the dysregulation of several key physiological systems, including the neuroendocrine, musculoskeletal, metabolic and immune/inflammatory system [51]. Recent longitudinal studies in various cohorts of older non-transplant adults suggest the latter as a key pathway [6,52–55]. Complex alterations in the innate and adaptive immune system are hypothesized to create a state of chronic low-grade systemic inflammation, which induces frailty and a higher susceptibility for chronic conditions, disability and mortality [51]. Causality of the inflammatory pathway in frailty has to date only scarcely been explored [49,56,57]. Moreover, evidence on a similar etiological pathway for mild cognitive impairment (MCI) is emerging [58] with one recent study identifying that MCI (assessed using the Montreal Cognitive Assessment Tool) was present in 64% of heart failure patients who were frail pre-transplant and in 33% of those who were not physically frail [59]. Studies in patients with end-stage heart failure that incorporated cognitive assessment in the FP improve its predictive validity for adverse outcomes [59]. Research has illuminated that MCI can accelerate the development of disability, which is predictive of hospitalization and mortality [60–63]. Thus, research exploring the interrelationships of frailty and MCI, their evolution, and joint predictive ability for negative outcomes is essential to advance frailty-screening methods [58,64]. At this point, transplant candidates with cognitive impairments are best followed up with a geriatric assessment to determine the cause of cognitive decline, followed by a personal, evidence based, multimodal intervention.

Additionally, studies show that frail patients use more healthcare resources compared to robust individuals. Frailty has therefore been recognized as a long-term condition leading to a range of adverse outcomes for individual patients and high healthcare expenses for the wider society [36,43,65–67]. Thus, research is needed to examine the impact of frailty on resource use and the cost-effectiveness of transplantation.

5. Conclusion

This systematic review demonstrates that frailty assessment in heart transplant candidates, as well as heart failure patients requiring mechanical circulatory support, is feasible and provides clinical prognostic value. Yet, its practical translation into transplant medicine is in its infancy. The evidence on poor outcomes of frail transplant candidates and a potential increased economic burden suggest an urgent need for transplant professionals to pay attention to the syndrome. Nevertheless, there is a need for more studies investigating frailty in the field of cardiac transplantation to allow any official recommendation for transplant list eligibility.

The authors declare no conflicts of interest. This state of the art systematic review was conducted without specific funding sources.

References

- Partridge JS, Harari D, Dhesei JK. Frailty in the older surgical patient: a review. *Age Ageing* 2012;41:142–7.
- Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC. Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. *Lancet Oncol* 2012;13:e437–44.
- Robinson TN, Walston JD, Brummel NE, Deiner S, Brown CH, Kennedy M, Hurria A. Frailty for Surgeons: review of a National Institute on Aging conference on frailty for specialists. *J Am Coll Surg* 2015;221:1083–92.
- Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001;56:M146–56.
- Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. *Lancet* 2013;381:752–62.
- Chen X, Mao G, Leng SX. Frailty syndrome: an overview. *Clin Interv Aging* 2014;9:433–41.
- Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. *J Heart Lung Transplant* 2016;35:1–23.
- United Network for Organ Sharing (UNOS)—Organ Procurement and Transplantation Network (OPTN); 2014.
- European Renal Association—European Dialysis and Transplant Association (ERA-EDTA). Annual reports; 2013.
- Koller M, Stampf S, Rick J, Achermann R, Steiger J. Swiss transplant cohort study report (May 2008–December 2013); 2014.
- Goldstein DR. The graying of organ transplantation. *Am J Transplant* 2012;12:2569–70.
- Abecassis M, Bridges ND, Clancy CJ, et al. Solid-organ transplantation in older adults: current status and future research. *Am J Transplant* 2012;12:2608–22.
- Jha SR, Ha HS, Hickman LD, Hannu M, Davidson PM, Macdonald PS, Newton PJ. Frailty in advanced heart failure: a systematic review. *Heart Fail Rev* 2015;20:553–60.
- Rodriguez-Manas L, Fearnt C, Mann G, et al. Searching for an operational definition of frailty: a Delphi method based consensus statement: the frailty operative definition-consensus conference project. *J Gerontol A Biol Sci Med Sci* 2013;68:62–7.
- Gordon AL, Masud T, Gladman JR. Now that we have a definition for physical frailty, what shape should frailty medicine take? *Age Ageing* 2014;43:8–9.
- Robinson TN, Walston JD, Brummel NE, Deiner S, Brown CH, Kennedy M, Hurria A. Frailty for surgeons: review of a National Institute on Aging conference on frailty for specialists. *J Am Coll Surg* 2015;221:1083–92.
- Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. *J Gerontol A Biol Sci Med Sci* 2004;59:255–63.
- Cesari M, Gambassi G, van Kan GA, Vellas B. The frailty phenotype and the frailty index: different instruments for different purposes. *Age Ageing* 2014;43:10–2.
- Walston JD, Bandeen-Roche K. Frailty: a tale of two concepts. *BMC Med* 2015;13:185.
- Exterkatte L, Slegtenhorst BR, Seyda M, et al. Frailty and transplantation. *Transplantation* 2015;100:727–33.
- Chow WB, Rosenthal RA, Merkow RP, Ko CY, Esnaola NF, P. American College of Surgeons National Surgical Quality Improvement, S. American Geriatrics. Optimal pre-operative assessment of the geriatric surgical patient: a best practices guideline from the American College of Surgeons National Surgical Quality Improvement Program and the American Geriatrics Society. *J Am Coll Surg* 2012;215:453–66.
- Rockwood K. What would make a definition of frailty successful? *Age Ageing* 2005;34:432–4.
- Jones DM, Song X, Rockwood K. Operationalizing a frailty index from a standardized comprehensive geriatric assessment. *J Am Geriatr Soc* 2004;52:1929–33.
- Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. *J Gerontol A Biol Sci Med Sci* 2007;62:722–7.
- Rockwood K, Hogan DB, MacKnight C. Conceptualisation and measurement of frailty in elderly people. *Drugs Aging* 2000;17:295–302.
- Rockwood K, Mitnitski A. Frailty defined by deficit accumulation and geriatric medicine defined by frailty. *Clin Geriatr Med* 2011;27:17–26.
- Rockwood K, Andrew M, Mitnitski A. A comparison of two approaches to measuring frailty in elderly people. *J Gerontol A Biol Sci Med Sci* 2007;62:738–43.
- Hii TB, Lainchbury JG, Bridgman PG. Frailty in acute cardiology: comparison of a quick clinical assessment against a validated frailty assessment tool. *Heart Lung Circ* 2015;24:551–6.
- Salter ML, Gupta N, Massie AB, et al. Perceived frailty and measured frailty among adults undergoing hemodialysis: a cross-sectional analysis. *BMC Geriatr* 2015;15:52–8.
- Jha SR, Hannu MK, Chang S, et al. The prevalence and prognostic significance of frailty in patients with advanced heart failure referred for heart transplantation. *Transplantation* 2016;100:429–36.
- Madan SA, Fida N, Barman P, et al. Frailty assessment in advanced heart failure. *J Card Fail* 2016;22:840–4.
- Reeves GR, Whellan DJ, Patel MJ, et al. Comparison of frequency of frailty and severely impaired physical function in patients >=60 years hospitalized with acute decompensated heart failure versus chronic stable heart failure with reduced and preserved left ventricular ejection fraction. *Am J Cardiol* 2016;117:1953–8.
- Vidan MT, Blaya-Novakova V, Sanchez E, Ortiz J, Serra-Rexach JA, Bueno H. Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. *Eur J Heart Fail* 2016;18:869–75.
- Lupon J, Gonzalez B, Santaeguenia S, et al. Prognostic implication of frailty and depressive symptoms in an outpatient population with heart failure. *Rev Esp Cardiol* 2008;61:835–42.
- Khan H, Kalogeropoulos AP, Georgiopoulos VV, et al. Frailty and risk for heart failure in older adults: the health, aging, and body composition study. *Am Heart J* 2013;166:887–94.
- McNallan SM, Singh M, Chamberlain AM, et al. Frailty and healthcare utilization among patients with heart failure in the community. *JACC Heart Fail* 2013;1:135–41.
- Boxer R, Kleppinger A, Ahmad A, Annis K, Hager D, Kenny A. The 6-minute walk is associated with frailty and predicts mortality in older adults with heart failure. *Congest Heart Fail* 2010;16:208–13.

- [38] Pulignano G, Del Sindaco D, Di Lenarda A, et al. Usefulness of frailty profile for targeting older heart failure patients in disease management programs: a cost-effectiveness, pilot study. *J Cardiovasc Med* 2010;11:739–47.
- [39] Dunlay SM, Park SJ, Joyce LD, et al. Frailty and outcomes after implantation of left ventricular assist device as destination therapy. *J Heart Lung Transplant* 2014;33:359–65.
- [40] Chung CJ, Wu C, Jones M, et al. Reduced handgrip strength as a marker of frailty predicts clinical outcomes in patients with heart failure undergoing ventricular assist device placement. *J Card Fail* 2014;20:310–5.
- [41] Rubenstein LZ, Stuck AE, Siu AL, Wieland D. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. *J Am Geriatr Soc* 1991;39:85–165 [discussion 175–185].
- [42] Musso CG, Jauregui JR, Macias Nunez JF. Frailty phenotype and chronic kidney disease: a review of the literature. *Int Urol Nephrol* 2015;47:1801–7.
- [43] Harrison JK, Clegg A, Conroy SP, Young J. Managing frailty as a long-term condition. *Age Ageing* 2015;44:732–5.
- [44] Goldraich L, Alba AC, Foroutan F, MacIver J, Ross H. Frailty phenotype is associated with decreased survival as predicted by the Seattle heart failure model in heart failure patients referred for advanced therapies. Poster presentation, annual meeting International Society for Heart and Lung Transplantation; 2015.
- [45] Rumer KK, Saraswathula A, Melcher ML. Prehabilitation in our most frail surgical patients: are wearable fitness devices the next frontier? *Curr Opin Organ Transplant* 2016;21:188–93.
- [46] Bendayan M, Bibas L, Levi M, Mullie L, Forman DE, Afilalo J. Therapeutic interventions for frail elderly patients: part II. Ongoing and unpublished randomized trials. *Prog Cardiovasc Dis* 2014;57:144–51.
- [47] Bibas L, Levi M, Bendayan M, Mullie L, Forman DE, Afilalo J. Therapeutic interventions for frail elderly patients: part I. Published randomized trials. *Prog Cardiovasc Dis* 2014;57:134–43.
- [48] Kelaiditi E, van Kan GA, Cesari M. Frailty: role of nutrition and exercise. *Curr Opin Clin Nutr Metab Care* 2014;17:32–9.
- [49] Theou O, Stathokostas L, Roland KP, Jakobi JM, Patterson C, Vandervoort AA, Jones GR. The effectiveness of exercise interventions for the management of frailty: a systematic review. *J Aging Res* 2011;2011:569194–229.
- [50] Michel JP, Cruz-Jentoft AJ, Cederholm T. Frailty, exercise and nutrition. *Clin Geriatr Med* 2015;31:375–87.
- [51] McElhaney J, Fulop T, Pawelec G, et al. Frailty, inflammation and immunosenescence. In: Theou O, Rockwood K, editors. *Frailty in aging: biological, clinical and social implications*. Basel: Karger Libri; 2015.
- [52] Collerton J, Martin-Ruiz C, Davies K, et al. Frailty and the role of inflammation, immunosenescence and cellular ageing in the very old: cross-sectional findings from the Newcastle 85+ study. *Mech Ageing Dev* 2012;133:456–66.
- [53] Leng SX, Xue QL, Tian J, Walston JD, Fried LP. Inflammation and frailty in older women. *J Am Geriatr Soc* 2007;55:864–71.
- [54] Leng SX, Xue QL, Tian J, Huang Y, Yeh SH, Fried LP. Associations of neutrophil and monocyte counts with frailty in community-dwelling disabled older women: results from the Women's Health and Aging Studies I. *Exp Gerontol* 2009;44:511–6.
- [55] Li H, Manwani B, Leng SX. Frailty, inflammation, and immunity. *Aging Dis* 2011;2:466–73.
- [56] Gale CR, Baylis D, Cooper C, Sayer AA. Inflammatory markers and incident frailty in men and women: the English Longitudinal Study of Ageing. *Age (Dordr)* 2013;35:2493–501.
- [57] Singer JP, Diamond JM, Gries CJ, et al. Frailty phenotypes, disability, and outcomes in adult candidates for Lung transplantation. *Am J Respir Crit Care Med* 2015;192:1325–34.
- [58] Halil M, Cemal Kizilarslanoglu M, Emin Kuyumcu M, Yesil Y, Cruz Jentoft AJ. Cognitive aspects of frailty: mechanisms behind the link between frailty and cognitive impairment. *J Nutr Health Aging* 2015;19:276–83.
- [59] Jha SR, Hannu MK, Gore K, et al. Cognitive impairment improves the predictive validity of physical frailty for mortality in patients with advanced heart failure referred for heart transplantation. *J Heart Lung Transplant* 2016;35:1092–100.
- [60] Auyeung TW, Lee JS, Kwok T, Woo J. Physical frailty predicts future cognitive decline – a four-year prospective study in 2737 cognitively normal older adults. *J Nutr Health Aging* 2011;15:690–4.
- [61] Jacobs JM, Cohen A, Ein-Mor E, Maaravi Y, Stessman J. Frailty, cognitive impairment and mortality among the oldest old. *J Nutr Health Aging* 2011;15:678–82.
- [62] Drame M, Novella JL, Jolly D, et al. Rapid cognitive decline, one-year institutional admission and one-year mortality: analysis of the ability to predict and inter-tool agreement of four validated clinical frailty indexes in the SAFEs cohort. *J Nutr Health Aging* 2011;15:699–705.
- [63] Yassuda MS, Lopes AJ, Cachioni M, Falcao DV, Batistoni SS, Guimaraes VA. Frailty criteria and cognitive performance are related: data from the FIBRA study in Ermelino Matarazzo, São Paulo, Brazil. *J Nutr Health Aging* 2012;16:55–61.
- [64] Robertson DA, Savva GM, Kenny RA. Frailty and cognitive impairment—a review of the evidence and causal mechanisms. *Ageing Res Rev* 2013;12:840–51.
- [65] Lyndon H. Reframing frailty as a long-term condition. *Nurs Older People* 2015;27:32–9.
- [66] Ilinca S, Calciolari S. The patterns of health care utilization by elderly Europeans: frailty and its implications for health systems. *Health Serv Res* 2015;50:305–20.
- [67] Rapp T, Sirven N. The dynamics of hospital use among older people: evidence for Europe using SHARE data. Document de Travail No 2014/01; 2014 [<http://lare-efi.u-bordeaux4.fr/IMG/pdf/SirvenRapp2014.pdf>].
- [68] Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. *Age Ageing* 2011;40:423–9.